Repligen Plans $1.5 Billion Acquisition of BioLife, Adding Cell Therapy Preservation and Transport Capabilities

The success of cell therapy depends not only on whether cells can fight disease, but also on whether they can be safely frozen and transported after leaving the laboratory and retain their function after thawing. Bioprocessing equipment provider Repligen is preparing to bring this critical part of the chain into its business: the company has entered into a definitive agreement with BioLife Solutions under which Repligen will acquire BioLife at an enterprise value of approximately $1.5 billion, expanding its presence in the cell and gene therapy manufacturing market.

Under the transaction terms, each BioLife share will be exchanged for $11.25 in cash and 0.1442 shares of Repligen stock, equivalent to $31 per share at the time of the announcement. The total consideration consists of approximately 64% Repligen stock and 36% cash, representing a 24% premium to BioLife’s 90-day volume-weighted average share price through July 21. The boards of directors of both companies have unanimously approved the transaction.

BioLife’s core value lies in cell preservation and processing. Its CryoStor line of preservation media is used to reduce damage to cells during freezing, storage, and thawing. The company says the product line has supported 18 commercially approved therapies and is used in most industry-sponsored cell therapy trials in the United States. For therapies that depend heavily on the quality of living cells, preservation media are consumables purchased repeatedly with each production batch, making them more likely to generate stable recurring revenue.

Repligen’s existing business covers biopharmaceutical manufacturing technologies including filtration, fluid management, chromatography, process analytics, and proteins. After adding BioLife, the company can extend its upstream and process-stage tools into cell preservation, storage and transport, and other processing steps, while using its existing global sales network to promote BioLife products, particularly by strengthening coverage in the Asia-Pacific market. This reflects how competition in the cell and gene therapy industry is expanding from therapy development into the infrastructure that supports mass production and distribution.

On the financial side, Repligen estimates that the transaction can generate at least $20 million in synergies in the first year after closing, rising to at least $30 million in the second year, from sources including reductions in public-company costs, improved administrative efficiency, and manufacturing and supply-chain integration. The company also expects adjusted earnings per share to increase by at least $0.05 in the first year and by at least $0.25 in the second year. These figures remain management’s forward-looking estimates, and whether they can be achieved depends on the pace of integration, customer retention, and market demand.

The transaction is expected to close in the fourth quarter of 2026, but remains subject to BioLife shareholder approval, regulatory clearance, and other customary closing conditions. Figures for the number of trials currently supported by BioLife products and the extent of future market growth also come primarily from the company’s own statements. Until the transaction formally closes, regulatory review, share-price fluctuations, and whether the manufacturing and commercial teams can be integrated smoothly remain unresolved uncertainties surrounding the acquisition.